COBALT-60 BEAM THERAPY

Technical Report · Sat Oct 31 04:00:00 EST 1959

OSTI ID:4293841

Smith, I H; MacDonald, J C.F.

Clinical experiences using the first commercially produced kilocurie cobalt-80 therapy unit are reviewed. Data cover a seven-year period. It is concluded that the physical advantages of high-energy gamma radiation over x rays in the conventional energy range are paralleled by clinical advantages. In radically treated cases, however, the initial tolerance of tumor tissue is slightly, higher under the high-energy gamma irradiation. Encouraging resuits are reported in the treatment of intrinsic carcinoma of the larynx, esophagus, mouth, and bladder. Physical data are included for the Theratron Junior Hectocurie Cobalt-60 Unit which was designed for use at a 55 cm source-to-tumor distance and is suitable for limited circumaxial-rotation and arc therapy and for fixed-field therapy. (C.H.)

• Research Organization: Ontario Cancer Foundation, London, Can.
• NSA Number: NSA-13-006086
• OSTI ID: 4293841
• Report Number(s): A/CONF.15/P/214; AECL-624
• Country of Publication: Country unknown/Code not available
• Language: English

Related Subjects

BIOLOGY AND MEDICINE
CANCER
COBALT 60
ECONOMICS
ENERGY RANGE
GAMMA RADIATION
MEDICINE
PRODUCTION
RADIOSENSITIVITY
RADIOTHERAPY
TISSUES
TUMORS
X RADIATION